Developing personalized therapeutics targeting molecular pathways activated in cancer.

 

Latest News

Tolero Pharmaceuticals announces Worldwide Agreement with Sanofi for the In-license of Alvocidib (Flavopiridol) - May 1, 2013 Tolero's Drug Development Pipeline Highlighted in Poster Presentations at the AACR 2013 Annual Meeting - April 10, 2013

Tolero Pharmaceuticals Spotlighted as an Emerging Company in BioCentury - January 13, 2013 Clinical Cancer Research Article Demonstrates SGI-7079 Sensitizes Lung Cancer Cells to Clinically Approved Anti-Cancer Agents - January 7, 2013

© 2012 Tolero Pharmaceuticals, Inc. - All Rights Reserved